THE DEVELOPMENT OF NOVEL NON-PEPTIDE PROTEASOME INHIBITORS FOR THE TREATMENT OF SOLID TUMORS
The proteasome is a large protein complex which is responsible for the majority of protein degradation in eukaryotes. Following FDA approval of the first proteasome inhibitor bortezomib for the treatment of multiple myeloma (MM) in 2003, there has been an increasing awareness of the significant ther...
Main Author: | |
---|---|
Format: | Others |
Published: |
UKnowledge
2018
|
Subjects: | |
Online Access: | https://uknowledge.uky.edu/pharmacy_etds/87 https://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1091&context=pharmacy_etds |